Solana

Solana CROIC

The Cash Return on Invested Capital (CROIC) of Solana (HSDT) as of Oct 21, 2026 is -20.37 %. In the previous year, Cash Return on Invested Capital (CROIC) was -1,031.37 % — a change of -98.03% (higher).

CROIC

-20.37 %

YoY

-98.03%

Last updated:

Cash Return on Invested Capital (CROIC) of Solana is 2025 -20.37 % . Cash Return on Invested Capital (CROIC) of Solana was 2024 -1,031.37 % . It decreases by -98.03% higher compared to the previous year.

The Solana CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-84.92 USD
Jan 1, 2019
-328.75 USD
Jan 1, 2020
-297.85 USD
Jan 1, 2021
-119.39 USD
Jan 1, 2022
-173.43 USD
Jan 1, 2023
-433.94 USD
Jan 1, 2024
-1,031.37 USD
Jan 1, 2025
-20.37 USD
The Solana CROIC history
YEARCROICYoY
-20.37 %-98.03%
-1,031.37 %+137.67%
-433.94 %+150.21%
-173.43 %+45.26%
-119.39 %-59.92%
-297.85 %-9.40%
-328.75 %+287.13%
-84.92 %-128.20%
301.11 %-184.55%
-356.11 %-25.09%
-475.41 %-99.30%
-68,179.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Solana Stock analysis

What does Solana do? Helius Medical Technologies develops and markets the PoNS device, a portable neuromodulation stimulator for neurological wellness. The company focuses on non-invasive platform technologies that enhance the brain's healing ability. The PoNS device is authorized as a class II medical device in Canada for short-term treatment of chronic balance deficits caused by mild-to-moderate traumatic brain injury, used alongside physical therapy. It delivers non-invasive neurostimulation to the tongue to induce neuromodulation. Helius Medical Technologies targets healthcare providers and rehabilitation centers that treat patients with traumatic brain injury. The company's product is designed for use in clinical settings under professional guidance, specifically for patients requiring short-term balance deficit therapy. The PoNS device is positioned as a complementary treatment within physical therapy protocols for neurological rehabilitation. The firm's revenue model is based on the sale of the PoNS device to healthcare institutions and rehabilitation facilities. These institutions purchase the device for use in their treatment programs, leveraging its non-invasive neurostimulation technology to address balance deficits in patients with mild-to-moderate traumatic brain injury. The company's focus on neurological wellness through non-invasive solutions drives its commercial strategy. Solana is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Solana stock

Cash Return on Invested Capital (CROIC) of Solana is -20.37 % in 2025.

Cash Return on Invested Capital (CROIC) of Solana changed from -1,031.37 % to -20.37 %, representing a -98.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Solana since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Solana with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Solana

All Key Metrics — Solana